Abbott said the HeartMate 3 is the safest iteration yet of any left ventricular assist device, or LVAD, a type of mechanical heart pump introduced in the 1960s and refined over the last six decades.

GlobalData predicts the cardiovascular medical device market will reach $86.5bn by 2030 while the LVAD market will reach $2.24bn by 2033. Abbott’s HeartMate 3 is the current market leader in the ...

CorWave today announced the world's first human implantation of its left ventricular assist device (LVAD) in Australia.

Patients in the study were randomized with either receiving the HeartMate 3 or Abbott’s older heart pump, HeartMate II. It is the first LVAD trial to examine five-year outcomes and surpasses a ...

Physicians from three top institutions report an abrupt and highly troubling increase over the last two years in the incidence of pump thrombosis in patients who have received the HeartMate II ...

January 21, 2010 (Silver Spring, Maryland) — Thoratec's HeartMate II is the first continuous-flow left-ventricular assist device (LVAD) approved by the FDA for transplant-ineligible heart ...

Cite this: Less Bleeding, Clotting With HeartMate 3 LVAD - Medscape - Apr 07, 2017. Authors and Disclosures. Authors and Disclosures Journalist Marlene Busko. Freelance writer, Medscape and Heartwire ...

ABBOTT PARK, Ill., Aug. 28, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) announced today it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev™ HeartMate 3 ™ Left ...

On Friday, Illinois-based Abbott Labs announced that the Food and Drug Administration has approved a new use for its HeartMate 3 LVAD that allows the device to be prescribed for long-term ...

Abbott is recalling a communication system that monitors heart failure patients implanted with its Heartmate 3 left ventricular assist device (LVAD) due to a risk that the system could ...

The HeartMate 3 left ventricular assist device (LVAD) was approved for pediatric patients with advanced heart failure, Abbott announced.. The approval covers both bridge to transplant and ...